Physician profile
Roy R Danks
NPI 1306812029
$4,062.11
in general payments reported to CMS, 2019-2025
11 companies · $62.63 in 2025
The $62.63 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,612 · 2021: $50.69 · 2022: $123 · 2023: $30.70 · 2024: $182 · 2025: $62.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $3,587.23 | 2019 | |
| Abbott Laboratories | $218.59 | 2024-2025 | I-Stat |
| Allergan, INC. | $98.88 | 2022 | |
| Zimmer Biomet Holdings, INC. | $26.42 | 2025 | Sternalock |
| Melinta Therapeutics, LLC | $25.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.41 | 2022 | |
| Smith+Nephew, INC. | $23.64 | 2021 | |
| Tela Bio, INC. | $17.37 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Kci USA, INC. | $16.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.33 | 2023 | Xarelto |
| Kls-Martin L.P. | $10.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Danks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.